ImmunityBio presented data showing its ANKTIVA plus BCG treatment outperformed two FDA-approved bladder cancer therapies, Adstiladrin and INLEXZO. The ANKTIVA combo achieved a 69.7% complete response rate versus 53.4% for Adstiladrin, with a longer median response duration (22.1 vs 9.7 months). Compared to INLEXZO, ANKTIVA had a similar response rate but significantly fewer treatment-related adverse events (61.7% vs 83.5%). These results suggest ANKTIVA could offer better efficacy and safety for patients with BCG-unresponsive non-muscle invasive bladder cancer, potentially impacting treatment choices.
Global Fight League (GFL) has launched a public investment campaign powered by DealMaker, allowing fans and investors to buy preferred stock and gain ownership in a new team-based MMA league. The league plans to start its inaugural season in 2026 wit...
Cava Group is set to report its Q1 2026 earnings with analysts expecting earnings per share (EPS) of $0.17, a 22.7% decline from last year's $0.22. Despite the EPS drop, revenue is projected to grow strongly by 26.1% to about $418.5 million, reflecti...
Vishay Intertechnology will present its latest passive components, semiconductors, and system-level solutions at PCIM Europe 2026 in Nuremberg, focusing on electrification, energy efficiency, and system integration. Highlights include advanced resist...
Kering has published its monthly update on the total number of shares and voting rights as of May 15, 2026. The company reports 123,420,778 shares composing its capital and 176,812,408 theoretical voting rights, with 176,010,581 exercisable voting ri...
The global smart ports market is projected to expand from $1.6 billion in 2025 to $7.3 billion by 2032, growing at a CAGR of 23.6%. This growth is fueled by increasing global trade, demand for operational efficiency, and sustainability efforts. Smart...
